公开(公告)号：US20090012499A1

公开(公告)日：2009-01-08

申请号：US11815684

申请日：2006-02-06

申请人： Kunio Miyatake ,  Kazuo Komamura ,  Sumio Kiyoto

发明人： Kunio Miyatake ,  Kazuo Komamura ,  Sumio Kiyoto

IPC分类号： A61M31/00 ,  A61B5/00

CPC分类号： A61K38/30

摘要： The present invention relates to novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (IGF-1). More specifically, the present invention relates to method for improving cardiovascular function and symptoms in a patient with chronic severe heart failure by administering IGF-1 to the patient for a certain period, wherein no options for treating the disorder the patient remain other than heart transplantation.

摘要翻译： 本发明涉及通过使用胰岛素样生长因子-1（IGF-1）治疗慢性严重心力衰竭的新方法。 更具体地，本发明涉及通过向患者施用IGF-1一段时间来改善患有慢性严重心力衰竭的患者的心血管功能和症状的方法，其中除了心脏移植之外，治疗病症的方法不存在 。

公开(公告)号：US6036972A

公开(公告)日：2000-03-14

申请号：US949864

申请日：1997-10-14

申请人： Toshikazu Nakamura ,  Kazuo Komamura ,  Kunio Miyatake

发明人： Toshikazu Nakamura ,  Kazuo Komamura ,  Kunio Miyatake

IPC分类号： A61K38/18 ,  A61K38/00

CPC分类号： A61K38/1833

摘要： The invention describes to a method of treating a patient with dilated cardiomyopathy comprising administering an effective amount of Hepatocyte Growth Factor (HGF).

摘要翻译： 本发明描述了治疗患有扩张型心肌病的患者的方法，包括施用有效量的肝细胞生长因子（HGF）。

公开(公告)号：US20080317720A1

公开(公告)日：2008-12-25

申请号：US11911466

申请日：2006-04-14

申请人： Noritoshi Nagaya ,  Kunio Miyatake ,  Kenji Kangawa ,  Masaharu Kataoka

发明人： Noritoshi Nagaya ,  Kunio Miyatake ,  Kenji Kangawa ,  Masaharu Kataoka

IPC分类号： A61K35/12 ,  C12N5/06 ,  A61P9/00

CPC分类号： A61L27/3843 ,  A61K35/12 ,  A61L27/3804 ,  C12N5/0667 ,  C12N2501/165 ,  C12N2501/34 ,  C12N2533/90

摘要： An objective of the present invention is to provide methods for producing progenitor cells which show a high proliferation ability ex vivo and promote neovascularization or myocardium regeneration, by culturing pluripotent cells in a medium containing adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). Moreover, another objective of the present invention is to provide the progenitor cells and uses thereof. In order to solve the above problems, the inventors of the present application have successfully developed a novel culture technique for producing progenitor cells from adipose tissues more efficiently compared to the conventional techniques, by using adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). The progenitor cells produced by the present inventors are specialized cells having a potent proliferation ability, a revascularization ability, and a myocardium regeneration ability, and have the property of not differentiating into adipocytes even if subjected to differentiation induction into adipocytes. Therefore, the progenitor cells of the present invention can be effective pharmaceutical agents for intractable diseases in the brain, lung, liver, kidney and the like.

摘要翻译： 本发明的目的是提供通过在含有肾上腺髓质素（AM）和/或血管内皮生长因子（VEGF）的培养基中培养多能细胞来产生离体显示高增殖能力并促进新生血管形成或心肌再生的祖细胞的方法 ）。 此外，本发明的另一个目的是提供祖细胞及其用途。 为了解决上述问题，本申请的发明人通过使用肾上腺髓质素（AM）和/或血管内皮生长因子（AM）和/或血管内皮生长因子（AM），成功地开发了一种新型的培养技术，用于与常规技术相比更有效地从脂肪组织产生祖细胞 VEGF）。 由本发明人生产的祖细胞是具有有效增殖能力，血运重建能力和心肌再生能力的特殊细胞，即使进行脂肪细胞分化诱导，也具有不分化成脂肪细胞的性质。 因此，本发明的祖细胞可以是脑，肺，肝，肾等中难治性疾病的有效药剂。

公开(公告)号：US20090105171A1

公开(公告)日：2009-04-23

申请号：US11885639

申请日：2006-03-07

申请人： Noritoshi Nagaya ,  Kunio Miyatake ,  Kenji Kangawa ,  Shinsuke Murakami

发明人： Noritoshi Nagaya ,  Kunio Miyatake ,  Kenji Kangawa ,  Shinsuke Murakami

IPC分类号： A61K31/7088 ,  A61P43/00

CPC分类号： A61K38/22

摘要： [Problems to be Solved] An objective of the present invention is to provide methods for regenerating or repairing damaged tissues using adrenomedullin. Another objective is to provide pharmaceutical agents that comprise adrenomedullin as an active ingredient for regenerating or repairing damaged tissues.[Means for Solving the Problems] To solve the above problems, the present inventors administered adrenomedullin (hereinafter indicated as AM) or physiological saline to C57BL/6 mice, and counted the numbers of mononuclear cells and Sca-1-positive cells in the blood. The result showed that AM increased the numbers of mononuclear cells and stem cell antigen-1-positive cells in the blood. It was also shown that by administering AM to a mouse model of pulmonary emphysema and a rat model of acute myocardial infarction, the quantity of bone marrow-derived cells that migrated and settled into the damaged tissues increased, and the recruited bone marrow cells differentiated into blood vessels, alveoli, and cardiac muscle at the lesion sites. Further, decrease in infarct size, suppression of the enlargement of alveolar diameter, and improvement of organ functions were confirmed in the models of myocardial infarction and pulmonary emphysema.

摘要翻译： [待解决的问题]本发明的目的是提供使用肾上腺髓质素再生或修复受损组织的方法。 另一个目标是提供包含肾上腺髓外素作为活性成分的药剂，用于再生或修复受损组织。 解决问题的手段为了解决上述问题，本发明人对C57BL / 6小鼠施用肾上腺髓质素（以下称为AM）或生理盐水，并计数血液中的单核细胞数和Sca-1阳性细胞数 。 结果表明，AM增加了血液中单核细胞和干细胞抗原-1阳性细胞的数量。 还表明，通过对小鼠肺气肿模型和急性心肌梗死的大鼠模型给予AM，迁移并沉降到受损组织中的骨髓来源的细胞数量增加，并且募集的骨髓细胞分化为 病变部位的血管，肺泡和心肌。 此外，在心肌梗死和肺气肿模型中证实了梗死面积的减少，肺泡直径的增大的抑制和器官功能的改善。